Japan regulatory nod clears way to AnGes gene therapy trial for lymphoedema
This article was originally published in Scrip
Executive Summary
The Japanese venture AnGes MG's most advanced pipeline project, the gene-based biologic therapy Collatagene (beperminogene perplasmid), has received regulatory approval in Japan to enter clinical development for the additional indication of lymphoedema.